Ara
Toplam kayıt 533, listelenen: 521-530
KEYFORM-008: Coformulated favezelimab and pembrolizumab (MK4280A) versus chemotherapy in relapsed/refractory classical Hodgkin lymphoma.
(Lippincott Williams & Wilkins, 2023)
...
Long-term course of COVID-19 vaccination-related headache: A prospective multicenter follow-up study
(SAGE Publications Ltd, 2023)
...
Real-life experiences with galcanezumab disclosed new predictors for response
(SAGE Publications Ltd, 2023)
...
Vascular comorbidity and cognition in migraine
(SAGE Publications Ltd, 2023)
...
Zilovertamab vedotin (MK 2140) in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Early results from the phase 2 waveLINE-004 study.
(Lippincott Williams & Wilkins, 2023)
...
Idarubicin versus daunorubicin versus mitoxantrone for induction chemotherapy in acute myeloid leukemia: Patient registration study of Turkish society of hematologyacute myeloid leukemia working group
(American Society of Hematology, 2023)
Introduction: Standard induction chemotherapy in newly diagnosed acute myeloid leukemia (AML) includes a combination of standard-dose cytarabine and an anthracycline (idarubicin [IDA], daunorubicin [DNR], or mitoxantrone ...
Acute myeloid leukemia in elderly, unfit patients: Analysis of Turkish AML prospective registry database, on behalf of acute leukemia working group of Turkish society of hematology
(American Society of Hematology, 2023)
Objective: Low dose Ara-C and hypomethylating agents (HMAs) - decitabine (DEC) and azacitidine (AZA) - have made it possible to treat more elderly patients with acute myeloid leukemia (AML). Both HMAs demonstrated efficacy ...
Open-label, randomized, phase 3 study of coformulated favezelimab and pembrolizumab versus chemotherapy in patients with relapsed or refractory classical hodgkin lymphoma refractory to anti-PD-1 therapy: Keyform-008
(American Society of Hematology, 2023)
Background: The importance of PD-1 therapy in relapsed or refractory (R/R) classical Hodgkin Lymphoma (cHL) is well established, with PD-1 inhibitors such as pembrolizumab being a standard of care option for patients. ...
Prospective real-world outcomes of acute myeloid leukemia
(American Society of Hematology, 2023)
Background: It is evident that treatment outcomes improve with the clinical studies, in this study we aimed to investigate the demographics and treatment modalities of the acute myeloid leukemia (AML) patients in a large ...